Brazil
2

Life sciences

SPLaw

Nous ne pouvons afficher que des informations limitées pour ce cabinet. Nous affichons des informations plus complètes pour les cabinets suivants :

Souto Correa Advogados logo
Souto Correa Advogados
Mattos Filho logo
Mattos Filho
Lefosse Advogados logo
Lefosse Advogados
Noted for its ‘knowledge of the market’, ‘flexibility in negotiation and innovation in solutions’, ’SPLaw combines IP, life sciences, and technology expertise to advise multinational and Brazilian life sciences companies on an array of legal matters. Typical mandates for the firm include advising on transactions, regulatory issues, disputes, IP mandates, and clinical trials. Benny Spiewak is highly regarded for his experience in IP matters; he has regularly assists clients from the pharma, medical devices, biotech, and other life sciences segments with patents issues, such as post-grant oppositions, and appeals before the public trade mark office. The recent addition of  Guillermo Glassman, who previously worked in-house at EMS Pharmaceuticals, has bolstered the team’s litigation capabilities. Senior associate Daniela Jambor is a specialist in Brazilian regulation of genetically modified organisms and medical cannabis.
L’éditorial du Legal 500

Témoignages

Collectés indépendamment par l'équipe de recherche du Legal 500.

  • ‘SPLaw is an firm specialised in the area of ​​healthcare and life sciences with differentiated quality and performance in the legal market. It performs excellently and always handles work with a technical basis, providing insights beyond what is expected. Another important point to highlight is its technical competence and sense of priority. They are at the forefront of discussions in this market.’

  • ‘Benny Spiewak has excellent knowledge and a highly differentiated performance in healthcare and life sciences. He is a pioneer in the market.’

Clients clés

  • AstraZeneca / Alexion
  • Boehringer Ingelheim

Points forts

  • Advising Organon on the $65m manufacturing, co-marketing, distribution, and license agreement entered with Finland-based Orion Pharmaceuticals, which secured Organon rights for Sandrena.
  • Advising Teva’s Active Pharmaceutical Ingredients Industry (TAPI) unit on the intellectual property system for active pharmaceutical ingredients.